Samsung ECG Monitor Application with Irregular Heart Rhythm Notification

The Samsung ECG Monitor Application with Irregular Heart Rhythm Notification feature utilizes photoplethysmography on a compatible smartwatch to opportunistically detect signs of atrial fibrillation by analyzing pulse rate variability and alert users. Upon notification or user initiative, the application enables the recording of a single-lead ECG for rhythm classification, aiming to provide informational insights to adults for potential consultation with healthcare professionals.

The Samsung ECG Monitor Application with Irregular Heart Rhythm Notification (IHRN) Feature is an over-the-counter, software-only mobile medical application designed for adults aged 22 and older for informational use. It operates on compatible Samsung Galaxy Watches and Phones, utilizing a photoplethysmography (PPG) sensor in the watch to opportunistically monitor the user's pulse rate data when they are still. The application analyzes beat-to-beat intervals from these bio-photonic signals to identify episodes of irregular heart rhythms suggestive of atrial fibrillation (AFib). If such an episode is detected, the IHRN feature provides a notification on the wearable, prompting the user to record an electrocardiogram (ECG). Following an IHRN prompt or at the user's initiative, the application can create, record, and display a single-channel ECG, similar to a Lead I ECG, using electrodes on the watch. This ECG data is then analyzed to classify the rhythm as AFib or sinus rhythm, or as inconclusive if criteria are not met. The data, including notification history and ECGs, is stored and can be shared as a PDF with healthcare providers. Clinical validation of the IHRN feature in 810 at-risk subjects showed a subject-level sensitivity of 68.0% and specificity of 98.8% for AFib detection, with a tachogram-level positive predictive value of 95.7%. The unchanged ECG function maintains an AFib sensitivity of 98.1% and sinus rhythm specificity of 100%. The application is not intended for users with other known arrhythmias and should not replace traditional diagnostic methods or be used for clinical decision-making without consulting a healthcare professional.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the impact of user activity levels, beyond "when the user is still," on the accuracy of the PPG-based irregular heart rhythm detection algorithm?; How does the device's performance in detecting AFib vary across different demographic groups (e.g., age, skin tone, comorbidities) not explicitly detailed in the summary?; What are the specific criteria or thresholds used by the algorithm to classify a tachogram as indicative of AFib, and how were these optimized to balance sensitivity and specificity for the IHRN feature?; Considering the opportunistic nature of data acquisition, what is the typical frequency and duration of monitoring required to achieve the reported sensitivity for AFib detection in real-world use?; What mechanisms are in place to manage and mitigate potential false positives from the IHRN feature, particularly given its 68% sensitivity, and how does this influence user behavior and subsequent ECG recording?